Iovance Biotherapeutics, Inc.

303 articles about Iovance Biotherapeutics, Inc.

• RXi Pharmaceuticals Enters into Material Transfer Agreement with Iovance Biotherapeutics to Study its Self-Delivering RNAi Technology for the Advancement of Immuno-Oncology Therapeutics

  5/11/2018

  Synergies between RXi's self-delivering RNAi (sd-rxRNA®) therapeutic platform and Iovance's TIL cell therapy approach will be explored preclinically

• IOVANCE INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Iovance Biotherapeutics, Inc. - IOVA

  3/3/2018

  Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq. announces that KSF has commenced an investigation into Iovance Biotherapeutics, Inc.

• 

  2 Bay Area Biotechs That Jumped While Its Peers Cratered

  2/7/2018

  Since Friday, the stock market has been volatile, to say the least.

• Iovance Biotherapeutics Announces Closing of $172.5M Common Stock Public Offering

  1/30/2018

  Iovance intends to use the proceeds from this offering to fund its ongoing clinical trials for its current product candidates, including its ongoing Phase 2 clinical trials of LN-144,

• Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $150M of Common Stock

  1/25/2018

  The offering is expected to close on or about January 29, 2018, subject to customary closing conditions.

• Iovance Biotherapeutics Announces Public Offering of Common Stock - Jan. 25, 2018

  1/25/2018

  Iovance intends to use the proceeds from this offering to fund its ongoing clinical trials for its current product candidates, including its ongoing Phase 2 clinical trials of LN-144.

• Iovance Biotherapeutics Expands Pipeline of TIL Therapies Into Lung Cancer

  12/13/2017

  The company also announced that a Phase 2 study in PD-1/PDL-1 naïve NSCLC patients will initiate in the first half of 2018.

• Iovance Biotherapeutics Announces Manufacturing Decision, Provides Clinical Updates and Highlights Pipeline Expansion at Analyst Day 2017

  12/13/2017

  Additionally, the company’s proprietary Generation 2 (Gen 2) manufacturing process has now been selected for all ongoing and future TIL clinical development.

• BioLife Solutions Executes Supply Agreement with Iovance Biotherapeutics

  12/13/2017

  BioLife Solutions today announced that it has executed an agreement to supply its CryoStor cell freeze media and HypoThermosol cell storage and shipping media to Iovance Biotherapeutics.

• Iovance Biotherapeutics to Webcast Analyst Day on Wednesday, December 13, 2017

  12/7/2017

  The event will highlight Iovance’s lead clinical programs.

• Iovance Biotherapeutics Announces New LN-144 Phase II Clinical Data from Metastatic Melanoma Trial to be Presented at SITC Meeting

  11/9/2017

  The data shows that administration of the company’s Generation 2 (Gen 2) manufacturing process in nine efficacy-evaluable metastatic melanoma patients resulted in a disease control rate (DCR) of 78%, which includes 3 confirmed partial responders (PRs) and a fourth PR awaiting confirmation.

• Iovance Biotherapeutics Reports Third Quarter 2017 Financial Results

  11/1/2017

  The company will host a conference call at 4:30pm ET today.

• Iovance Biotherapeutics to Host Conference Call to Discuss Third Quarter 2017 Financial Results and Provide a Corporate Update on Tuesday, October 31, 2017

  10/25/2017

  Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET.

• 

  3 Under-the-Radar Bay Area Biotechs That Could Double in 2018

  10/18/2017

  Biotech stocks are generally viewed as highly volatile. Of course, along with volatility comes the possibility for huge upside rewards.

• Iovance Biotherapeutics Announces Closing Of $57.5 Million Common Stock Public Offering

  9/26/2017

• Iovance Biotherapeutics Announces Pricing Of Its Public Offering Of $50 Million Of Common Stock

  9/21/2017

• Iovance Biotherapeutics Announces Public Offering Of Common Stock

  9/20/2017

• Iovance Biotherapeutics Announces Approval Of First Clinical Trial Application By Competent Authority In Netherlands For A Phase II Trial Of LN-145 For The Treatment Of Patients With Cervical Cancer

  9/13/2017

• Iovance Biotherapeutics Partners With TrakCel For Personalized Patient Product Management

  9/11/2017

• Iovance Biotherapeutics Enters Into A Research Collaboration Focused On Hematologic Malignancies With The Ohio State University Comprehensive Cancer Center

  9/7/2017